human neutrophil elastase  (Athens Research)

Journal: iScience

Article Title: CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion

doi: 10.1016/j.isci.2026.115334

Figure Lengend Snippet: CGM23 stability against plasma and enzymes and pharmacodynamics (A–F), Stability of peptides in plasma (A) or in the presence of cathepsin D (B), cathepsin B (C), cathepsin K (D), neutrophil elastase (E), trypsin (F) in vitro . After incubation of peptides with plasma or enzymes for 8 h, the residual amount of peptides was determined by HPLC. (G) Time course of CGM23 and EK1C4 concentration in plasma (LLOQ; 8.65 ng/ml) after intranasal administration to mice (CGM23, 0.865 mg/kg; EK1C4, 1 mg/kg). ∗ p < 0.05. Statistical analysis was performed using unpaired two-tailed Student’s t test test. Black bars represent the mean concentrations. LLOQ, lower limit of quantification. Identical symbols indicate sequential samples from the same mouse.

Article Snippet: Peptides adjusted to 100 μM with water were mixed with human plasma, cathepsin B (Sigma, SRP6414) 67 nM, cathepsin D (Sigma, SRP6415) 200 nM, cathepsin K (Sigma, SRP6561) 200 nM, neutrophil elastase (Elastin Products Company Inc., SE563) 100 nM, and trypsin (Sigma, SRP6311) 200 nM, respectively, and incubated at 37°C for 8 hours.

Techniques: Clinical Proteomics, Drug discovery, In Vitro, Incubation, Concentration Assay, Two Tailed Test